Etra Health, Inc. — SEC Form D Filing
Etra Health, Inc. filed an SEC Form D on October 2, 2026, reporting $750K raised in Healthcare Technology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 2, 2026
- Amount reported
- $750K
- Round stage
- Pre-Seed
- Industry
- Healthcare Technology
- Website
- https://www.etrahealth.com/
What the company does
Securities: Simple Agreement for Future Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Many patients with chronic illnesses lack adequate support and report low satisfaction with their current treatment, often receiving fragmented, crisis-driven attention. This leads to increased crisis calls and hidden workloads for practice staff, leaving practices uncompensated for much of their chronic care management.
Solution
Etra provides an evidence-based chronic care management system that transforms crisis management into billable, continuous care. It automates patient outreach, tracks detailed progress, summarizes patient data for care teams, and generates compliant, billable reports for services like CCM and RPM.
Why now
The shift towards value-based care models and the increasing prevalence of chronic conditions necessitate more efficient and scalable solutions for continuous patient management. Advances in AI and digital health tools make it possible to automate and streamline these processes, offering a sustainable way for practices to provide proactive care and generate revenue.
Verdict
This cleared because it offered a tangible, revenue-generating solution to an acute operational pain point for a defined subset of healthcare providers, not because it represented a broad market disruption. Investors were implicitly betting on the company's ability to navigate billing complexities and secure adoption within specialist clinics, converting previously uncompensated staff time into billable services. The upside was inherently limited by the niche focus on specific practice types and the competitive landscape for value-based care enablement, which could cap growth before broader market penetration.
Source: SEC EDGAR Form D filing